Zocor Generic Dose Dependence: Lipitor Aims High While Crestor Goes Low
Executive Summary
Payers are targeting only the lowest dose of Pfizer's Lipitor in their efforts to switch patients to generic Zocor (simvastatin), Senior VP-Global Pharmaceutical Finance Peter Brandt said
You may also be interested in...
Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight
Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13
Crestor, Zocor Comparison May Be More Useful Than ASTEROID – Editorial
A trial comparing high doses of AstraZeneca's Crestor and Merck's Zocor would be more informative than the open label, single-arm ASTEROID study evaluating the effects of high-intensity Crestor on regression of coronary atherosclerosis, according to an editorial in the March 13 issue of the Journal of the American Medical Association